CME Group Inc. (CME)

Servicios financieros — bolsa de derivados y cámara de compensación

The world's largest derivatives exchange operator, with a network-effect and regulatory-scale moat, trades at 25× on adjusted operating earnings — the market pays for quality, and the expected 5-year return is +4%.

Moat Compounder estimates the intrinsic value of CME Group Inc. (CME) at $316 per share on a five-year horizon. With the stock at $281.03 at 2026-09-04 close, the expected total return is 4.4% per year: fairly valued. The analysis draws on 10-K FY2025 (period ended Dec-31-2025) and 10-Q Q2 2026 (period ended Jun-30-2026). Analysis dated 2026-07-24.

Price
$281.03
at 2026-09-04 close
Intrinsic value (5y, base)
$316
Total annual return (5y)
4.4%
2.4% price · 2.0% div
Status (nominal)
Fairly valued
Margin of safety
No margin

The essentials

  • Global leading derivatives exchange with a systemically important designated central counterparty clearing house — the business combines transaction fees with recurring investment income on ~US$158 billion of customer margin funds.
  • GAAP operating margin of 65.1% (TTM) with modest, sustained expansion; the margin adjusted for investment income is 78.4%.
  • Return on invested capital above the 10% bar, with a wide, stable moat: long-term exclusive licenses on the S&P/Nasdaq/Russell indices, the CME Term SOFR benchmark rate, and liquidity network effects.
  • Additional structural growth ahead: U.S. Treasury (Dec-2026) and repo (Jun-2027) central clearing mandates, the 2026 launch of CME Securities Clearing, and the prediction-markets joint venture with FanDuel.
  • At $281, the expected 5-year total return is +4% — Fairly valued.
Health: Solid
Price $281 at 2026-09-04 closeMarket Cap $101.5 bnEnterprise Value $102.7 bnNet debt $1.1 bnEV/NOPAT (today) 25.3x

Intrinsic value — two valuation methods

No margin of safety
Price market
$281
DCF value today
$313
+11.4% vs price
Multiples value today
$280
-0.4% vs price

Total return at 5 years: 4.4%/year = 2.4% appreciation + 2.0% dividend. The target price ($316) is ex-dividend; the $30 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($281) and the other below.

Pillars of the analysis

The verdict — today vs 5 years

Today — expensive, no margin of safety: at $281 trades ~0.4% above its value discounted to today (~$280); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — En valor: the target price ($316) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$177.

Thesis

The business

Capital-light financial-market-infrastructure business, with GAAP operating margins of 65.1% (TTM) in modest expansion and an additional recurring income stream from investing customer margin funds. Return on invested capital above the 10% bar, with a wide, stable moat.

The valuation

Valued on EV/NOPAT over adjusted operating earnings that incorporate recurring net investment income on customer margin funds, normalized for the non-recurring gain on the sale of the OSTTRA joint venture. At an exit multiple of 20×, the 5-year value is $316, versus a market price of $281.

The margin of safety

It trades close to intrinsic value, far from the required margin of safety. The expected 5-year total return (appreciation plus dividend, via IRR) is +4%: +2% from appreciation and +2% from dividends.

What to watch

The central disconfirmer is the interest-rate cycle: if the Federal Reserve cuts aggressively, net investment income on customer margin funds contracts, taking with it a material portion of the adjusted margin that supports the current entry multiple. The second is price competition in cash markets (BrokerTec/EBS) and the emergence of digital-asset platforms and prediction markets that could erode volume at the margin.

Educational / informational. Does not constitute investment advice.

Other stocks we analyze